uniQure N.V. (QURE) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $27.77: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 1.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 18%; Below-average business quality.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate... Read more
Sell if holding. Engine safety override at $27.77: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 1.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 18%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.3/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 47d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent developments
updated 2026-06-13Recent Developments — uniQure N.V.
Latest news
- NEWS 7 Health Care Stocks With Whale Alerts In Today's Session — benzinga Jun 9, 2026 neutral
- NEWS Watching uniQure; Shares See A Spike In Volume, Endpoints News Reports "Acting FDA Commissioner Pledges To Prevent Polit — benzinga Jun 4, 2026 positive
- NEWS Replimune, Dell Technologies, NetApp And Other Big Stocks Moving Higher on Friday — benzinga May 29, 2026 positive
- NEWS 10 Health Care Stocks Whale Activity In Today's Session — benzinga May 12, 2026 neutral
- NEWS 'Makary's Time Atop FDA Over, Diamantas Named Acting Commissioner' - Politico — benzinga May 12, 2026 neutral
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $27.77: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 1.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 18%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $25.64. Score 5.3/10, moderate confidence.
Take-profit target: $33.87 (+22.9% upside). Prior stop was $25.64. Stop-loss: $25.64.
Quality below floor (1.8 < 4.0); Value-trap signals (2/5): Revenue declining (-11.6% YoY), Margin compression (op margin 1.5%).
uniQure N.V. trades at a P/E of N/A (forward -9.5). TrendMatrix value score: 7.5/10. Verdict: Sell.
21 analysts cover QURE with a consensus score of 4.0/5. Average price target: $39.
What does uniQure N.V. do?uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States....
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.